will be used to fund the repurchase of the existing notes and to finance the Group’s general corporate purposes, including, but not limited to, working capital requirements, capital expenditures, funding
registered capital by Baht 125 million. Paid up capital as of 30 June 2017 was 225 million baht to prepare for listing on the SET. The Company paid a dividend of Baht 67.60 million. Please be informed
’ Equities as of 31 December 2016 and 30 September 2017 were Baht 350.97 million and 835.04 million respectively. The proportion of Shareholders' Equity increased from the share capital and capital in excess
working capital management during 9M17, trade receivable turnover, inventory turnover as well as trade payable turnover were not meaningfully changed yoy. Leverage ratio has improved as illustrated by
debentures are a) investment in the new projects, b) repayment of debts, and c) working capital. (NWR188A) Interest expense of debentures for the third quarter of 2017 was Baht 17.01 million. On August 28
million baht from 2016. The increasing in shareholder’s equity was because the Company capital increase from General Mandate and share premium increased from increase capital. The Company debt to equity
was because the Company capital increase from General Mandate and share premium increased from increase capital. The Company debt to equity ratio stood at 1.58 times and the Interest-Bearing Debt ratio
million resulted increase of Bill of Exchange issued for providing more working capital. Other expenses increased of Baht 7.51 million mainly from consulting fee increased of Baht 1.59 million and loss on
increasing financial costs from short-term loans from other persons and other companies which were used for working capital of the business, amounted to Baht 279.64 million as of 31 December 2017. Income tax
จึงมีควำมเสี่ยงที่ผูล้งทนุอำจสูญเสียเงินลงทุนจ ำนวนมำก 2 นโยบำยกำรลงทุน: กองทุนจะเน้นลงทุนในหน่วยลงทุนของกองทุน Polar Capital Funds plc - Biotechnology ชนิดหน่วยลงทุน I US Dollar (กองทุนหลัก) ซึ่งมีน